Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
May 28, 2026

Mrna-1083 / mcombriax for in active immunization against influenza disease and COVID-19 in adults aged 50 years and older as of May 2026

MARA Rating Company May 28, 2026

Fylrevy / estetrol for in Hormone Replacement Therapy in Postmenopausal Women as of May 2026

MARA Rating Company May 28, 2026

Semaglutide for in Non-cirrhotic metabolic dysfunction-associated steatohepatitis with F2-F3 fibrosis as of May 2026

MARA Rating Company May 28, 2026

Tovorafenib for in Pediatric Low-Grade glioma as of May 2026

MARA Rating Company May 28, 2026

Relacorilant for in Platinum-Resistant Epithelial Ovarian Cancer as of May 2026

MARA Rating Company May 28, 2026

Pegzilarginase-nbln for in hyperargininemia in arginase 1 deficiency as of May 2026

MARA Rating Company May 28, 2026

Zolgensma / onasemnogene abeparvovec for in 5Q Spinal Muscular Atrophy as of May 2026

MARA Rating Company May 28, 2026

Yuviwel / navepegritide for in Pediatric Achondroplasia With Open Epiphyses as of May 2026

MARA Rating Company May 28, 2026

Nadofaragene firadenovec for in High-Grade BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer With Carcinoma in Situ as of May 2026

MARA Rating Company May 28, 2026

Icotyde / icotrokinra for moderate-to-severe plaque psoriasis in patients aged 12+ years and ³40 kg as of April 2026

MARA Rating Company May 28, 2026